Phase 4Recruiting
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)
- Sponsor
- Huijie Zhang (Academic or other)
- Enrollment
- 820 planned
- Conditions
- Type 2 Diabetic Kidney Disease
- Interventions
- empagliflozin; Finerenone; Mazdutide; Finerenone Placebo; Mazdutide Placebo; Angiotensin Receptor Blocker (ARB)
- Ages
- adults, older adults
- Registry
- NCT07775846
Full record on ClinicalTrials.gov
From the registry
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone. The primary comparisons include G2 vs. G1, G3 vs. G1, G4 vs. G2, and G4 vs. G3, designed to evaluate the superiority of triple therapy over dual therapy, and quadruple therapy over triple therapy, in reducing the urine albumin-to-creatinine ratio (UACR).
Primary outcomes
- Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered